JINXIN FERT.GRP HD-00001 Total Liabilities

Latest as of December 2025: €4.76 Billion EUR ≈ $5.57 Billion USD

JINXIN FERT.GRP HD-00001 total liabilities. Based on the latest financial reports, JINXIN FERT.GRP HD-00001 (3NX) has total liabilities worth €4.76 Billion EUR (≈ $5.57 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of JINXIN FERT.GRP HD-00001 to evaluate the company's liquid asset resilience ratio.

Total Liabilities of JINXIN FERT.GRP HD-00001 (2021–2025)

Total liabilities of JINXIN FERT.GRP HD-00001 from 2021 to 2025. This chart illustrates how JINXIN FERT.GRP HD-00001's total liabilities have evolved over time, based on quarterly financial data.

JINXIN FERT.GRP HD-00001 Competitors by Total Liabilities

The table below lists competitors of JINXIN FERT.GRP HD-00001 ranked by their total liabilities.

Company Country Total Liabilities
Anhui Huilong Agricultural Means of Production Co Ltd
SHE:002556
China CN¥7.73 Billion
CK Power Public Company Limited
BK:CKP
Thailand ฿34.71 Billion
Vulcan Steel Ltd
AU:VSL
Australia AU$787.93 Million
Lotte Tour Dev
KO:032350
Korea ₩1.80 Trillion
SUPER HI INTERNATIONAL HOLDING LTD. American Depositary Shares
NASDAQ:HDL
USA $354.24 Million
Chongqing QinAn M&E PLC
SHG:603758
China CN¥1.09 Billion
MNTN, Inc.
NYSE:MNTN
USA $68.41 Million
Jdd Tech New Mat Co Ltd
SHE:301538
China CN¥243.00 Million

Liability Composition Analysis (2021–2025)

This chart breaks down JINXIN FERT.GRP HD-00001's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see 3NX asset base.

Liquidity & Leverage Metrics

JINXIN FERT.GRP HD-00001 Total Liabilities Ratios Explained

JINXIN FERT.GRP HD-00001 total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 0.87 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.52 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.34 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how JINXIN FERT.GRP HD-00001's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for JINXIN FERT.GRP HD-00001 (2021–2025)

The table below shows the annual total liabilities of JINXIN FERT.GRP HD-00001 from 2021 to 2025.

Year Total Liabilities Change
2025-12-31 €4.76 Billion
≈ $5.57 Billion
+2.95%
2024-12-31 €4.63 Billion
≈ $5.41 Billion
-1.74%
2023-12-31 €4.71 Billion
≈ $5.51 Billion
-27.51%
2022-12-31 €6.50 Billion
≈ $7.60 Billion
+59.52%
2021-12-31 €4.07 Billion
≈ $4.76 Billion
--

About JINXIN FERT.GRP HD-00001

F:3NX Germany Medical Care Facilities
Market Cap
$740.26 Million
€633.18 Million EUR
Market Cap Rank
#11121 Global
#1286 in Germany
Share Price
€0.25
Change (1 day)
-6.72%
52-Week Range
€0.21 - €0.29
All Time High
€1.75
About

Jinxin Fertility Group Limited, an investment holding company, provides assisted reproductive services (ARS) in China and internationally. The company provides two treatment solutions, including artificial insemination that is performed with either husband's sperm or a donor sperm; and IVF technology, whereby fertilization is achieved through conventional in vitro fertilization and embryo transfe… Read more